Explore

Trendline Trendline
Merck KGaA Begins Phase 3 Trial for New Colorectal Cancer Treatment

Merck KGaA Begins Phase 3 Trial for New Colorectal Cancer Treatment

Merck KGaA Begins Phase 3 Trial for New Colorectal Cancer Treatment
Trendline Trendline
Kelun-Merck Partnership Validates TROP2-Keytruda Combination in Lung Cancer with Improved Survival Rates

Kelun-Merck Partnership Validates TROP2-Keytruda Combination in Lung Cancer with Improved Survival Rates

Kelun-Merck Partnership Validates TROP2-Keytruda Combination in Lung Cancer with Improved Survival Rates
Trendline Trendline
Fulgent Genetics Releases Abstract on FID-007 for Head and Neck Cancer at ASCO 2026

Fulgent Genetics Releases Abstract on FID-007 for Head and Neck Cancer at ASCO 2026

Fulgent Genetics Releases Abstract on FID-007 for Head and Neck Cancer at ASCO 2026
Trendline Trendline
Biogen and Denali Halt Development of Parkinson's Drug After Trial Failure

Biogen and Denali Halt Development of Parkinson's Drug After Trial Failure

Biogen and Denali Halt Development of Parkinson's Drug After Trial Failure
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO Meeting, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO Meeting, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO Meeting, Highlighting Antitumor Efficacy
Trendline Trendline
Obsidian Therapeutics Reports Positive Phase 2 Results for OBX-115 in Melanoma

Obsidian Therapeutics Reports Positive Phase 2 Results for OBX-115 in Melanoma

Obsidian Therapeutics Reports Positive Phase 2 Results for OBX-115 in Melanoma
Trendline Trendline
Precision BioSciences to Discuss New Hepatitis B Trial Data in Upcoming Webcast

Precision BioSciences to Discuss New Hepatitis B Trial Data in Upcoming Webcast

Precision BioSciences to Discuss New Hepatitis B Trial Data in Upcoming Webcast
Trendline Trendline
Biogen and Denali Halt Parkinson's Drug Development After Phase 2 Trial Failure

Biogen and Denali Halt Parkinson's Drug Development After Phase 2 Trial Failure

Biogen and Denali Halt Parkinson's Drug Development After Phase 2 Trial Failure
Trendline Trendline
Obsidian Therapeutics to Present Positive Phase 2 Results for OBX-115 in Advanced Melanoma at ASCO Meeting

Obsidian Therapeutics to Present Positive Phase 2 Results for OBX-115 in Advanced Melanoma at ASCO Meeting

Obsidian Therapeutics to Present Positive Phase 2 Results for OBX-115 in Advanced Melanoma at ASCO Meeting
Trendline Trendline
Servier to Present New Data on Rare Cancer Treatments at ASCO 2026

Servier to Present New Data on Rare Cancer Treatments at ASCO 2026

Servier to Present New Data on Rare Cancer Treatments at ASCO 2026
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting

Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting

Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting
Trendline Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomally Instable Tumors

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomally Instable Tumors

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomally Instable Tumors